U.S., May 5 -- ClinicalTrials.gov registry received information related to the study (NCT07565389) titled 'Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma' on March 09.
Brief Summary: This study is designed as a single-arm, open-label, phase II trial to evaluate the efficacy and safety of ivonescimab in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) who have progressed on prior an immune checkpoint inhibitor and platinum-based chemotherapy.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Nasopharyngeal Carcinoma (NPC)
Intervention:
DRUG: Ivonescimab 20 mg/kg
Subjects will receive intravenous ivonescimab at a dose of 20 mg/kg administered every 3 weeks ...